510(k) device
Dexcom G7 15 Day Continuous Glucose Monitoring System
Dexcom, Inc. · Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ, Class II) · First FDA decision Apr 9, 2025, newest Apr 9, 2025Diabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "G7 15 Day"
MAUDE reports
21,927
Brand "G7 15 Day", since 2015
PubMed studies
0
Mentioning "G7 15 Day"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Dexcom G7 15 Day Continuous Glucose Monitoring System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K243214 · Decided Apr 9, 2025 · 188 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38662CGS Administrators, LLCUpdated Sep 29, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38623Wellpoint FederalUpdated Jul 14, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38686WPS Insurance CorporationUpdated Jun 18, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38657Noridian Healthcare Solutions, LLCUpdated Oct 14, 2025
- Home Health Plans of Care: Monitoring Glucose Control in the Medicare Home Health Population with Type II Diabetes MellitusLocal determinationIn effectL35132Palmetto GBAUpdated Apr 9, 2025
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38743Palmetto GBAUpdated Jul 19, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38664First Coast Service Options, Inc.Updated Jun 21, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38617Novitas Solutions, Inc.Updated Jun 21, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "G7 15 Day", any status and sponsor, newest update first.
No registered device study names "G7 15 Day".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "G7 15 Day", and for the whole product code for context.
This brand
21,927 reports: 21,062 malfunction, 803 injury, 0 death
Whole product code QBJ
2,390,871 reports: 2,344,654 malfunction, 45,370 injury, 256 death
Newest reports for this brand
3004753838-2026-289493 · Received Oct 30, 2026 · Event dated Oct 11, 2026
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Device problem as coded: Wireless Communication Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
3004753838-2026-289491 · Received Oct 30, 2026 · Event dated Oct 2, 2026
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Device problem as coded: Wireless Communication Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
3004753838-2026-289461 · Received Oct 30, 2026 · Event dated Oct 18, 2026
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Device problem as coded: Wireless Communication Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2163-2026 · Started Apr 14, 2026 · Posted by FDA May 11, 2026
Reason given: A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the...
Cause as FDA categorized it: Software design · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Z-2164-2026 · Started Apr 14, 2026 · Posted by FDA May 11, 2026
Reason given: A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the...
Cause as FDA categorized it: Software design · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Published research
The most relevant PubMed records for "G7 15 Day"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code QBJ.
- Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc. · 510(k) 2026
- Dexcom G6 Continuous Glucose Monitoring (CGM) SystemDexcom, Inc. · De Novo 2023
- FreeStyle Libre 3 Continuous Glucose Monitoring SystemAbbott Diabetes Care, Inc. · 510(k) 2024
- FreeStyle Libre 2 Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.